Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Molecules ; 26(7)2021 Mar 28.
Article in English | MEDLINE | ID: mdl-33800673

ABSTRACT

Coffea arabica pulp (CP) is a by-product of coffee processing. CP contains polyphenols that have exhibited beneficial effects, including antioxidant and lipid-lowering effects, as well as enhanced insulin sensitivity, in in vitro and in vivo models. How polyphenols, as found in CP aqueous extract (CPE), affect type 2 diabetes (T2D) has not been investigated. Thus, the present study examined the potential antidiabetic, antioxidant, and renoprotective effects of CPE-rich polyphenols, using an experimental model of T2D in rats induced by a high-fat diet and a single low dose of streptozotocin. The T2D rats received either 1000 mg/kg body weight (BW) of CPE, 30 mg/kg BW of metformin (Met), or a combination treatment (CPE + Met) for 3 months. Plasma parameters, kidney morphology and function, and renal organic transport were determined. Significant hyperglycemia, hypertriglyceridemia, insulin resistance, increased renal lipid content and lipid peroxidation, and morphological kidney changes related to T2D were restored by both CPE and CPE + Met treatments. Additionally, the renal uptake of organic cation, 3H-1-methyl-4-phenylpyridinium (MPP+), was reduced in T2D, while transport was restored by CPE and CPE + Met, through an up-regulation of antioxidant genes and protein kinase Cα deactivation. Thus, CPE has antidiabetic and antioxidant effects that potentially ameliorate kidney function in T2D by preserving renal organic cation transport through an oxidative stress pathway.


Subject(s)
Antioxidants/pharmacology , Coffea/chemistry , Diabetes Mellitus, Experimental/drug therapy , Hyperglycemia/drug therapy , Hypoglycemic Agents/pharmacology , Metformin/pharmacology , Polyphenols/pharmacology , Animals , Antioxidants/isolation & purification , Carrier Proteins/agonists , Carrier Proteins/metabolism , Diabetes Mellitus, Experimental/etiology , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Experimental/pathology , Diet, High-Fat/adverse effects , Drug Combinations , Drug Synergism , Hyperglycemia/etiology , Hyperglycemia/metabolism , Hyperglycemia/pathology , Hypoglycemic Agents/isolation & purification , Insulin Resistance , Ion Transport/drug effects , Kidney/drug effects , Kidney/metabolism , Kidney/pathology , Lipid Peroxidation/drug effects , Male , Oxidative Stress/drug effects , Plant Extracts/chemistry , Polyphenols/isolation & purification , Rats , Rats, Wistar , Streptozocin/administration & dosage
2.
Mol Imaging Biol ; 21(1): 113-121, 2019 02.
Article in English | MEDLINE | ID: mdl-29869061

ABSTRACT

PURPOSE: There is an urgent need for the development of novel positron emission tomography (PET) tracers for glioma imaging. In this study, we developed a novel PET probe ([18F]VUIIS1018A) by targeting translocator protein (TSPO), an imaging biomarker for glioma. The purpose of this preclinical study was to evaluate this novel TSPO probe for glioma imaging. PROCEDURES: In this study, we synthesized [19F]VUIIS1018A and the precursor for radiosynthesis of [18F]VUIIS1018A. TSPO binding affinity was confirmed using a radioligand competitive binding assay in C6 glioma cell lysate. Further, dynamic imaging studies were performed in rats using a microPET system. These studies include displacement and blocking studies for ligand reversibility and specificity evaluation, and compartment modeling of PET data for pharmacokinetic parameter measurement using metabolite-corrected arterial input functions and PMOD. RESULTS: Compared to previously reported TSPO tracers including [18F]VUIIS1008 and [18F]DPA-714, the novel tracer [18F]VUIIS1018A demonstrated higher binding affinity and BPND. Pretreatment with the cold analog [19F]VUIIS1018A could partially block tumor accumulation of this novel tracer. Further, compartment modeling of this novel tracer also exhibited a greater tumor-to-background ratio, a higher tumor binding potential and a lower brain binding potential when compared with other TSPO probes, such as [18F]DPA-714 and [18F]VUIIS1008. CONCLUSIONS: These studies illustrate that [18F]VUIIS1018A can serve as a promising TSPO PET tracer for glioma imaging and potentially imaging of other solid tumors.


Subject(s)
Brain Neoplasms/diagnosis , Fluorine Radioisotopes/pharmacokinetics , Glioma/diagnosis , Positron-Emission Tomography/methods , Pyrazoles/pharmacokinetics , Pyrimidines/pharmacokinetics , Animals , Brain Neoplasms/pathology , Carrier Proteins/agonists , Carrier Proteins/metabolism , Disease Progression , Drug Evaluation, Preclinical , Glioma/pathology , Ligands , Magnetic Resonance Imaging , Male , Rats , Rats, Wistar , Receptors, GABA-A/metabolism , Tumor Cells, Cultured
3.
Am J Physiol Endocrinol Metab ; 312(6): E461-E470, 2017 06 01.
Article in English | MEDLINE | ID: mdl-28270444

ABSTRACT

α-Linolenic acid (ALA) supplementation or exercise training can independently prevent hepatic lipid accumulation and reduced insulin signaling; however, this may occur through different mechanisms of action. In the current study, obese Zucker rats displayed decreased phospholipid (PL) content in association with hepatic lipid abundance, and therefore, we examined whether ALA and exercise training would prevent these abnormalities differently to reveal additive effects on the liver. To achieve this aim, obese Zucker rats were fed control diet alone or supplemented with ALA and were sedentary or exercise trained for 4 wk (C-Sed, ALA-Sed, C-Ex, and ALA-Ex). ALA-Sed rats had increased microsomal-triglyceride transfer protein (MTTP), a protein required for lipoprotein assembly/secretion, as well as modestly increased PL content in the absence of improvements in mitochondrial content, lipid accumulation, or insulin sensitivity. In contrast, C-Ex rats had increased mitochondrial content and insulin sensitivity; however, this corresponded with minimal improvements in PL content and hepatic lipid accumulation. Importantly, ALA-Ex rats demonstrated additive improvements in PL content and hepatic steatosis, which corresponded with increased mitochondrial content, MTTP and apolipoprotein B100 content, greater serum triacylglyceride, and insulin sensitivity. Overall, these data demonstrate additive effects of ALA and exercise training on hepatic lipid accumulation, as exercise training preferentially increased mitochondrial content, while ALA promoted an environment conducive for lipid secretion. These data highlight the potential for combination therapy to mitigate liver disease progression.


Subject(s)
Carrier Proteins/agonists , Dietary Supplements , Liver/metabolism , Non-alcoholic Fatty Liver Disease/prevention & control , Obesity/diet therapy , Physical Conditioning, Animal , alpha-Linolenic Acid/therapeutic use , Animals , Apolipoprotein B-100/metabolism , Biomarkers/blood , Biomarkers/metabolism , Blotting, Western , Carrier Proteins/metabolism , Combined Modality Therapy , Insulin Resistance , Lipid Metabolism , Male , Microsomes, Liver/metabolism , Non-alcoholic Fatty Liver Disease/etiology , Obesity/metabolism , Obesity/physiopathology , Obesity/therapy , Phospholipids/metabolism , Random Allocation , Rats, Zucker , Triglycerides/blood
4.
Food Chem Toxicol ; 59: 303-10, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23811533

ABSTRACT

Microcystins (MCs) are a family of cyclic heptapeptides that are produced by blooming algae Microcystis. MCs have been implicated in the development of liver cancer, necrosis and even intrahepatic bleeding. Effective prophylactic approaches and complete removal of MCs are urgently needed. Accumulating evidence suggests that microcystin-LR (MC-LR)-induced damage is accompanied by oxidative stress. Supplementation of Se can enhance resistance to oxidative stress. Therefore, in the present study, we investigated the protective effects of κ-Selenocarrageenan (Se-Car), a kind of organic Se compound, in Balb/c mice exposed to MC-LR. Our results proved that Se-Car could significantly ameliorate the hepatic damage induced by MC-LR, including serum markers of liver dysfunction, oxidative damages and histological alterations. Furthermore, Se-Car could significantly alleviate the up-regulation of the molecular targets indicating mitochondrial dysfunction and endoplasmic reticulum stress induced by MC-LR. In conclusion, Se-Car showed clear protection against toxicity induced by MC-LR. Thus, Se-Car could be useful as a new category of anti-MC-LR toxicity reagent.


Subject(s)
Antitoxins/therapeutic use , Bacterial Toxins/antagonists & inhibitors , Carrageenan/therapeutic use , Hepatic Insufficiency/prevention & control , Liver/drug effects , Marine Toxins/antagonists & inhibitors , Microcystins/antagonists & inhibitors , Organoselenium Compounds/therapeutic use , Adaptor Proteins, Signal Transducing , Animals , Bacterial Toxins/toxicity , Biomarkers/blood , Carrier Proteins/agonists , Carrier Proteins/antagonists & inhibitors , Carrier Proteins/genetics , Carrier Proteins/metabolism , Cell Cycle Proteins , Endoplasmic Reticulum Stress/drug effects , Eukaryotic Initiation Factors , Hepatic Insufficiency/chemically induced , Hepatic Insufficiency/metabolism , Hepatic Insufficiency/pathology , Lipid Peroxidation/drug effects , Liver/metabolism , Liver/pathology , Liver/physiopathology , Male , Marine Toxins/toxicity , Mice , Mice, Inbred BALB C , Microcystins/toxicity , Microcystis/metabolism , Mitochondria, Liver/drug effects , Mitochondria, Liver/metabolism , Mitochondria, Liver/pathology , Oxidative Stress/drug effects , Phosphoproteins/agonists , Phosphoproteins/antagonists & inhibitors , Phosphoproteins/genetics , Phosphoproteins/metabolism , Random Allocation , Signal Transduction/drug effects , Survival Analysis
5.
Bioorg Med Chem Lett ; 23(11): 3358-63, 2013 Jun 01.
Article in English | MEDLINE | ID: mdl-23622982

ABSTRACT

The M2 isoform of pyruvate kinase is an emerging target for antitumor therapy. In this letter, we describe the discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as potent and selective PKM2 activators which were found to have a novel binding mode. The original lead identified from high throughput screening was optimized into an efficient series via computer-aided structure-based drug design. Both a representative compound from this series and an activator described in the literature were used as molecular tools to probe the biological effects of PKM2 activation on cancer cells. Our results suggested that PKM2 activation alone is not sufficient to alter cancer cell metabolism.


Subject(s)
Benzimidazoles/chemistry , Carrier Proteins/agonists , Membrane Proteins/agonists , Pyrimidinones/chemistry , Thyroid Hormones/agonists , Binding Sites , Carrier Proteins/metabolism , Cell Line , Computer-Aided Design , Drug Evaluation, Preclinical , High-Throughput Screening Assays , Humans , Kinetics , Membrane Proteins/metabolism , Molecular Docking Simulation , Protein Binding , Protein Structure, Tertiary , Pyrimidinones/chemical synthesis , Pyrimidinones/metabolism , Structure-Activity Relationship , Thyroid Hormones/metabolism , Thyroid Hormone-Binding Proteins
6.
Ukr Biokhim Zh (1999) ; 85(5): 137-48, 2013.
Article in Ukrainian | MEDLINE | ID: mdl-24479331

ABSTRACT

It is known that inflammatory cytokines, which level is significantly increased in the pathogenesis of multiple sclerosis (MS), as well as interferon-beta, which is used to treat autoimmune diseases, can inhibit cytochrome P450-dependent processes of detoxification and biotransformation. The uncontrolled decrease of the activity of these processes may have a negative affect on the state of patients, so it is urgent to study the functional state of the cytochrome P450 system and to develop effective means for its regulation in these conditions. The effect of vitamin D3 and efficiency of its composition with vitamins B1, B2, B6, PP, E, alpha-lipoic, alpha-linolenoic acid and mineral substances (Mg, Zn, Se) in prevention of a functional state changes of cytochrome P450- and b5-dependent systems of the rat brain and liver endoplasmic reticulum at EAE are investigated. It has been shown that the essential decrease of the level of these cytochromes is observed both in the brain and liver. In addition the level of activity of NADH- and NADPH-oxidoreductases, which are part of microsomal electron transport chain components and coupled with monooxigenases, was reduced. These changes confirm the disturbances of a redox state and functional activity of detoxication and biotransformation systems in the studied animal tissues. Supplement of vitamin D3 as well as the composition of biologically active substances, which we developed earlier, effectively eliminated the decrease of the level of cytochromes and activities of NADH-oxidoreductase in immunised rat tissues. Normalization of these disturbances can be explained by antioxidant and membrane-stabilizing properties of applied substances, and also by the ability to reduce the activity of inflammatory reactions by regulation of the level of inflammatory cytokines in rat organism at EAE. Thus the studied vitamin-mineral composition appeared to be more effective to normalize the found disturbances and it can be useful for prevention of exacerbations and for improvement of a status of patients with multiple sclerosis and other diseases, which are accompanied with hyperactivation of immune system.


Subject(s)
Cytochrome P-450 Enzyme System/metabolism , Encephalomyelitis, Autoimmune, Experimental/drug therapy , Magnesium/administration & dosage , Minerals/administration & dosage , Selenium/administration & dosage , Vitamins/administration & dosage , Zinc/administration & dosage , Animals , Brain/drug effects , Brain/enzymology , Brain/immunology , Carrier Proteins/agonists , Carrier Proteins/metabolism , Encephalomyelitis, Autoimmune, Experimental/chemically induced , Encephalomyelitis, Autoimmune, Experimental/enzymology , Encephalomyelitis, Autoimmune, Experimental/pathology , Freund's Adjuvant , Heme-Binding Proteins , Hemeproteins/agonists , Hemeproteins/metabolism , Liver/drug effects , Liver/enzymology , Liver/immunology , Male , Microsomes, Liver/drug effects , Microsomes, Liver/enzymology , Microsomes, Liver/immunology , Myelin Proteins , Rats , Rats, Wistar
7.
Biochem Pharmacol ; 85(2): 257-64, 2013 Jan 15.
Article in English | MEDLINE | ID: mdl-23103566

ABSTRACT

Although high-fructose corn syrup (HFCS-55) is the major sweetener in foods and soft-drinks, its potential role in the pathophysiology of diabetes and obesity ("diabesity") remains unclear. Peroxisome-proliferator activated receptor (PPAR)-δ agonists have never been tested in models of sugar-induced metabolic abnormalities. This study was designed to evaluate (i) the metabolic and renal consequences of HFCS-55 administration (15% wt/vol in drinking water) for 30 weeks on male C57Bl6/J mice and (ii) the effects of the selective PPAR-δ agonist GW0742 (1 mg/kg/day for 16 weeks) in this condition. HFCS-55 caused (i) hyperlipidemia, (ii) insulin resistance, and (iii) renal injury/inflammation. In the liver, HFCS-55 enhanced the expression of fructokinase resulting in hyperuricemia and caused abnormalities in known insulin-driven signaling events. In the kidney, HFCS-55 enhanced the expression of the NLRP3 (nucleotide-binding domain and leucine-rich-repeat-protein 3) inflammasome complex, resulting in caspase-1 activation and interleukin-1ß production. All of the above effects of HFCS-55 were attenuated by the specific PPAR-δ agonist GW0742. Thus, we demonstrate for the first time that the specific PPAR-δ agonist GW0742 attenuates the metabolic abnormalities and the renal dysfunction/inflammation caused by chronic HFCS-55 exposure by preventing upregulation of fructokinase (liver) and activation of the NLRP3 inflammasome (kidney).


Subject(s)
Carrier Proteins/metabolism , Dietary Carbohydrates/adverse effects , Disease Models, Animal , Hypoglycemic Agents/therapeutic use , Inflammasomes/drug effects , Kidney/drug effects , PPAR gamma/agonists , Animals , Carrier Proteins/agonists , Carrier Proteins/antagonists & inhibitors , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/etiology , Diabetes Mellitus, Type 2/physiopathology , Diabetic Nephropathies/immunology , Diabetic Nephropathies/metabolism , Diabetic Nephropathies/prevention & control , Fructokinases/metabolism , Fructose/administration & dosage , Fructose/adverse effects , Glucose/administration & dosage , Glucose/adverse effects , Inflammasomes/metabolism , Kidney/immunology , Kidney/metabolism , Kidney/physiopathology , Liver/drug effects , Liver/immunology , Liver/metabolism , Male , Mice , Mice, Inbred C57BL , NLR Family, Pyrin Domain-Containing 3 Protein , Seeds/chemistry , Thiazoles/therapeutic use , Zea mays/chemistry
8.
J Biomol Screen ; 17(2): 204-15, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21956172

ABSTRACT

The nicotinic acetylcholine receptors (nAChRs) are a member of the ligand-gated ion channel family and play a key role in the transfer of information across neurological networks. The X-ray crystal structure of agonist-bound α(7) acetylcholine binding protein (AChBP) has been recognized as the most appropriate template to model the ligand-binding domain of nAChR for studying the molecular mechanism of the receptor-ligand interactions. Virtual screening of the National Cancer Institute diversity set, a library of 1990 compounds with nonredundant pharmacophore profiles, using AutoDock against AChBPs revealed 51 potential candidates. In vitro radioligand competition assays using [(3)H] epibatidine against the AChBPs from the freshwater snails, Lymnaea stagnalis, and from the marine species, Aplysia californica and the mutant (AcY55W), revealed seven compounds from the list of candidates that had micromolar to nanomolar affinities for the AChBPs. Further investigation on α(7)nAChR expressing in Xenopus oocytes and on the recombinant receptors with fluorescence resonance energy transfer (FRET)-based calcium sensor expressing in HEK cells showed that seven compounds were antagonists of α(7)nAChR, only one compound (NSC34352) demonstrated partial agonistic effect at low dose (10 µM), and two compounds (NSC36369 and NSC34352) were selective antagonists on α(7)nAchR with moderate potency. These hits serve as novel templates/scaffolds for development of more potent and specific in the AChR systems.


Subject(s)
Carrier Proteins/agonists , Carrier Proteins/antagonists & inhibitors , Drug Evaluation, Preclinical/methods , Receptors, Nicotinic/metabolism , Algorithms , Animals , Aplysia , Binding Sites , Crystallography, X-Ray , Fluorescence Resonance Energy Transfer , HEK293 Cells , Humans , Ligand-Gated Ion Channels , Lymnaea , Oocytes , Protein Conformation , Receptors, Nicotinic/chemistry , Software , Xenopus
9.
J Biol Chem ; 283(36): 24748-59, 2008 Sep 05.
Article in English | MEDLINE | ID: mdl-18559343

ABSTRACT

The generation of reactive oxygen species is a central feature of inflammation that results in the oxidation of host phospholipids. Oxidized phospholipids, such as 1-palmitoyl-2-arachidonyl-sn-glycero-3-phosphorylcholine (OxPAPC), have been shown to inhibit signaling induced by bacterial lipopeptide or lipopolysaccharide (LPS), yet the mechanisms responsible for the inhibition of Toll-like receptor (TLR) signaling by OxPAPC remain incompletely understood. Here, we examined the mechanisms by which OxPAPC inhibits TLR signaling induced by diverse ligands in macrophages, smooth muscle cells, and epithelial cells. OxPAPC inhibited tumor necrosis factor-alpha production, IkappaBalpha degradation, p38 MAPK phosphorylation, and NF-kappaB-dependent reporter activation induced by stimulants of TLR2 and TLR4 (Pam3CSK4 and LPS) but not by stimulants of other TLRs (poly(I.C), flagellin, loxoribine, single-stranded RNA, or CpG DNA) in macrophages and HEK-293 cells transfected with respective TLRs and significantly reduced inflammatory responses in mice injected subcutaneously or intraperitoneally with Pam3CSK4. Serum proteins, including CD14 and LPS-binding protein, were identified as key targets for the specificity of TLR inhibition as supplementation with excess serum or recombinant CD14 or LBP reversed TLR2 inhibition by OxPAPC, whereas serum accessory proteins or expression of membrane CD14 potentiated signaling via TLR2 and TLR4 but not other TLRs. Binding experiments and functional assays identified MD2 as a novel additional target of OxPAPC inhibition of LPS signaling. Synthetic phospholipid oxidation products 1-palmitoyl-2-(5-oxovaleryl)-sn-glycero-3-phosphocholine and 1-palmitoyl-2-glutaryl-sn-glycero-3-phosphocholine inhibited TLR2 signaling from approximately 30 microm. Taken together, these results suggest that oxidized phospholipid-mediated inhibition of TLR signaling occurs mainly by competitive interaction with accessory proteins that interact directly with bacterial lipids to promote signaling via TLR2 or TLR4.


Subject(s)
Acute-Phase Proteins/metabolism , Carrier Proteins/metabolism , Lipopolysaccharide Receptors/metabolism , Lymphocyte Antigen 96/metabolism , Macrophages, Peritoneal/metabolism , Membrane Glycoproteins/metabolism , Phosphatidylcholines/pharmacology , Signal Transduction/drug effects , Toll-Like Receptor 2/metabolism , Toll-Like Receptor 4/metabolism , Acute-Phase Proteins/agonists , Acute-Phase Proteins/genetics , Acute-Phase Proteins/immunology , Animals , Carrier Proteins/agonists , Carrier Proteins/genetics , Carrier Proteins/immunology , Cell Line , Female , Flagellin/pharmacology , Guanosine/analogs & derivatives , Guanosine/pharmacology , Humans , I-kappa B Kinase/genetics , I-kappa B Kinase/immunology , I-kappa B Kinase/metabolism , Immunologic Factors/pharmacology , Lipopolysaccharide Receptors/genetics , Lipopolysaccharide Receptors/immunology , Lipopolysaccharides/pharmacology , Lymphocyte Antigen 96/agonists , Lymphocyte Antigen 96/genetics , Lymphocyte Antigen 96/immunology , Macrophages, Peritoneal/cytology , Macrophages, Peritoneal/immunology , Membrane Glycoproteins/agonists , Membrane Glycoproteins/genetics , Membrane Glycoproteins/immunology , Mice , Mice, Inbred BALB C , Oligodeoxyribonucleotides/pharmacology , Oxidation-Reduction/drug effects , Phosphatidylcholines/genetics , Phosphatidylcholines/immunology , Phosphorylation/drug effects , Poly I-C/pharmacology , RNA/pharmacology , Reactive Oxygen Species/immunology , Reactive Oxygen Species/metabolism , Signal Transduction/physiology , Toll-Like Receptor 2/agonists , Toll-Like Receptor 2/genetics , Toll-Like Receptor 2/immunology , Toll-Like Receptor 4/agonists , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/immunology , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/immunology , Tumor Necrosis Factor-alpha/metabolism , p38 Mitogen-Activated Protein Kinases/genetics
10.
Nucleosides Nucleotides Nucleic Acids ; 27(2): 173-85, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18205071

ABSTRACT

Conjugates of three components namely folic acid, poly(ethyleneglycol) and 3 '-azido-3 '-deoxythymidine (AZT) are presented. Folate-PEG units were coupled to AZT to facilitate delivery of the nucleoside into the cell. A convenient separation of the polydisperse PEGylated-folic acid regioisomers produced upon conjugation is described. This is to select for the active gamma-regioisomer over the inactive alpha-regioisomer. In vitro cytotoxicity assays were conducted against an ovarian cell line (A2780/AD) that overexpresses the folate receptor (FR) and compared to a FR free control cell line. Compared to AZT a approximately 20-fold greater potency against the resistant ovarian line was observed for the conjugates.


Subject(s)
Cytotoxins/chemical synthesis , Cytotoxins/pharmacology , Folic Acid/chemical synthesis , Folic Acid/pharmacology , Zidovudine/chemical synthesis , Zidovudine/pharmacology , Carrier Proteins/agonists , Cell Line , Cytotoxins/chemistry , Drug Evaluation, Preclinical , Drug Resistance/drug effects , Folate Receptors, GPI-Anchored , Folic Acid/chemistry , Polyethylene Glycols/chemical synthesis , Polyethylene Glycols/chemistry , Polyethylene Glycols/pharmacology , Receptors, Cell Surface/agonists , Zidovudine/chemistry
11.
Rev Invest Clin ; 42 Suppl: 137-40, 1990 Jul.
Article in English | MEDLINE | ID: mdl-19256153

ABSTRACT

Mammalian brain contains two types of benzodiazepine receptors namely the "central-type" receptor which forme part of the GABA-benzodiazepine receptor complex, and the so-called "peripheral-type" receptor found predominantly on mitocondrial membranes of astrocytes. Brain GABA-related benzodiazepine receptors are unchanged in hepatic encephalopathy. On the other hand, human and experimental hepatic encephalopathy are associated with increased densities of "peripheral type" benzodiazepine receptor. Results of several studies using agonists and antagonists of both types of benzodiazepine receptors are discussed in this review.


Subject(s)
Astrocytes/metabolism , Carrier Proteins/physiology , Hepatic Encephalopathy/metabolism , Receptors, GABA-A/physiology , Receptors, GABA/physiology , Animals , Astrocytes/pathology , Benzodiazepines/adverse effects , Carrier Proteins/agonists , Carrier Proteins/antagonists & inhibitors , Clinical Trials as Topic , Drug Evaluation, Preclinical , Flumazenil/therapeutic use , GABA Antagonists/therapeutic use , GABA-A Receptor Agonists , GABA-A Receptor Antagonists , Hepatic Encephalopathy/chemically induced , Hepatic Encephalopathy/drug therapy , Humans , Ligands , Mammals/metabolism , Mitochondria/metabolism , Mitochondria/pathology , Portacaval Shunt, Surgical/adverse effects , Rabbits , Rats , Receptors, GABA/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL